Tevimbra TM
Listen to the Pronunciation:
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional.
Active ingredients: tislelizumab
Pack: Tevimbra 100 mg/10 mL injection, 10 mL vial
Brand name
(ARTG)
: TEVIMBRA tislelizumab 100 mg/10 mL concentrated injection vialConsumer Medicine Information (CMI)
Read the CMI leaflet for facts you need to know before, during and after taking your medicine.
Listen to the audio transcription of the CMI leaflet.
For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).
What this medicine is used for
(ARTG)
Oesophageal squamous cell carcinoma (OSCC),TEVIMBRA in combination with platinum-based chemotherapy is indicated for the first-line treatment of patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma with a PD-L1 expression equal to or greater than 1%.,TEVIMBRA as monotherapy is indicated for the treatment of adult patients with unresectable, recurrent, locally advanced or metastatic oesophageal squamous cell carcinoma after prior chemotherapy.,Non-small cell lung cancer (NSCLC),TEVIMBRA in combination with pemetrexed and platinum containing chemotherapy is indicated for the first-line treatment of patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC), with PD-L1 expression equal to or greater than 50% but no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.,TEVIMBRA in combination with carboplatin and either paclitaxel or nab-paclitaxel is indicated for the first-line treatment of patients with locally advanced or metastatic squamous NSCLC.,TEVIMBRA as monotherapy is indicated for the treatment of patients with locally advanced or metastatic NSCLC after prior chemotherapy.,Gastric/Gastro-oesophageal Junction (G/GOJ) Adenocarcinoma,TEVIMBRA in combination with platinum and fluoropyrimidine-based chemotherapy, is indicated for the first-line treatment of adult patients with HER-2 negative locally advanced unresectable or metastatic gastric or gastro-oesophageal junction (G/GOJ) adenocarcinoma with a PD-L1 expression equal to or greater than 1%.,Nasopharyngeal carcinoma (NPC),TEVIMBRA in combination with gemcitabine and cisplatin is indicated for the first-line treatment of adult patients with recurrent or metastatic nasopharyngeal carcinoma (NPC).
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Injection, concentrated
- Intravenous Infusion
- Clear to slightly opalescent, colorless to slightly yellow solution.
Storage conditions
(ARTG)
- Store at 2 to 8 degrees Celsius
- Protect from Light
- Do not Freeze
- Refrigerate
- Do not Shake
- Shelf lifetime is 36 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is
- 1 x carton containing 1 x single-dose vial pack
Is this medicine subsidised ?
(PBS)
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on June, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient tislelizumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
